Dry eye disease Dry eye disease Platelet rich plasma Ocular surface disease
Conditions
Interventions
Platelet rich plasma of participants will be used 6 times/day for 3 months
Experimental Biological/Vaccine
Sponsors
Ratchadaphaiseksomphot fund
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Aged 18-80 years OSDI scores at least 13 with corneal staining > 5 spots or tear break-up time < or = 5 seconds in patients treated with autologous serum at least 3 months
Exclusion criteria
Exclusion criteria: Lid problems including lagophthalmos, ectropion, entropion trichiasis, distichiasis, epiblepharon Previuos history of ocular infection in 3 months Possibility to have problem with follow-up Possibility to have problem with applying platelet rich plasm Herpetic keratitis Thrombocytopenia, sepsis, chronic liver disease, anti-coagulation therapy including warfarin, dabigatran, heparin Hb < 11 mg/dl or Hct < 33% or platelet < 140,000 cell/mm2 History of ocular surgery within 1 month
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dry eye symptoms 1, 2, 3 months Ocular surface disease index score | — |
Secondary
| Measure | Time frame |
|---|---|
| Corneal staining 1, 2, 3 months Cornea NEI scale,Conjunctival staining 1, 2, 3 months Conjunctival NEI scale,Tear break up time 1, 2, 3 months Tear break up time,Tear production 1, 2, 3 months Schirmer test,Subbasal and dendritic cell density 1, 2, 3 months In vivo confocal microscopy,Side effect 1 wk, 1, 2, 3 months description | — |
Countries
Thailand
Contacts
Public ContactVannarut Satitpitakul
Faculty of Medicine, Chulalongkorn University
Outcome results
None listed